Intracranial activity of encorafenib and binimetinib followed by radiotherapy in patients with BRAF mutated melanoma and brain metastasis: Preliminary results of the GEM1802/EBRAIN-MEL phase II clinical trial

Marquez-Rodas, I.Arance, A.Berciano Guerrero, M. A.Diaz Beveridge, R.Alamo, M. D. C.Garcia Castano, A.Gonzalez Cao, M.Vidal, J.Puertolas Hernandez, T.Soria, A.Aguado De la Rosa, C.Sanchez Maurino, P.Valduvieco, I.Delgado Rico, R.Conde, A.Foro, P.Prada, P. J.Puertas, E.Alvarez Gonzalez, A.Berrocal, A.2025-01-072025-01-072021-09-210923-7534https://hdl.handle.net/10668/25882enIntracranial activity of encorafenib and binimetinib followed by radiotherapy in patients with BRAF mutated melanoma and brain metastasis: Preliminary results of the GEM1802/EBRAIN-MEL phase II clinical trialconference outputopen access10.1016/j.annonc.2021.08.14231569-8041https://doi.org/10.1016/j.annonc.2021.08.1423700527702057